Enrollment Continues in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe

MAPS Europe is delighted to announce that as of March 7, 2022, recruitment of patients into the MP18 study began at the Department of Psychiatry and Neurosciences in the Charité – Universitätsmedizin Berlin, in Berlin, Germany, one of the largest university hospitals in Europe. The study is led by Dr. Dimitris Repantis. 

Patient recruitment is expected to begin at sites for this study in London and Hamburg before the end of the month.